



SPARK TEL AVIV Educational Forum


Dr. Adi Elkeles

Founder and CEO, Trobix Bio

Spin-offing academic discovery – hard earned lessons from forming a startup company

Abstract

Spinning-off academic discoveries is a challenging process. The creation of an independent startup company, based on early stage innovation, taken directly from the corridors of an academic laboratory, is a huge undertaking. The multiple variables, different stakeholders and diversity of agendas are all mixed to a process that often does not result in a successful outcome. There are different approaches to creating such early stage startups. Dr. Adi Elkeles, former VP of business development at Ramot will compare these approaches and share his experience on the different barriers to be addressed, and ways to overcome them. He will also share his personal voyage to spinning-off a novel platform for tackling antimicrobial resistance, into a new startup - Trobix Bio. In his talk, Dr. Elkeles will describe the path taken to structure the business model used for fund raising, exemplify success and failure tails, and describe the key parameters that eventually led to the successful outcome.



Dr. Adi Elkeles is a senior executive with a proven track record in leading biomed entrepreneurship and innovation for close to 20 years. Till recently, Dr. Elkeles served as VP Business Development for life sciences at Ramot, where he led the business development, licensing and strategy for the life science

sector. Before joining Ramot, he was Chief Technology Officer and Chief Business Development Officer at Micromedic, a cancer diagnostic cluster company, where he led commercialization, in licensing and out licensing activities. Previously, Dr. Elkeles served as CEO of Zetiq Technologies Ltd., a cancer diagnostic company, where he evolved the company from a pre-clinical stage to having a fully commercial product and a portfolio of pipeline products in clinical stage. Prior to joining Zetiq, Dr. Elkeles held several managerial positions, leading pre-clinical development programs for anti-cancer at BiolineRx technology incubator and infectious diseases at XTLbio.

Dr. Elkeles holds a PhD degree from Tel Aviv University, an MBA from the College of Management, and has completed a post-doctoral fellowship at the Weizmann Institute of Science. He is an alumnus of the Paul Merage life science executive leadership program at UC Irvine, California.

Wednesday, 26 June 2019 at 17:00 KATZIR Hall, Green Biotechnology Building, Faculty of life sciences

SPARK TEL AVIV | WEB: http://spark-telaviv.tau.ac.il/ | TEL: 972-03-6407925 | Mail: sparktau@tauex.ac.il